Serum CEACAM1 Elevation Correlates with Melanoma Progression and Failure to Respond to Adoptive Cell Transfer...

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Malignant melanoma incidence is rising, necessitating improved screening and prognostic tools.
• Current treatments offer hope for metastatic melanoma, but clinical management is challenged by a lack of effective screening.
• Carcinine antigen 1 (CEACAM1) expression on melanoma cells predicts poor prognosis, with a secreted form (sCEACAM1) emerging as a potential biomarker.

Purpose of the Study:

• To investigate the prognostic role of serum CEACAM1 in melanoma.
• To correlate serum CEACAM1 levels with tumor burden in a preclinical model.
• To assess the relationship between serum CEACAM1 and response to immunotherapy in melanoma patients.

Main Methods:

• Utilized a mice xenograft model of human melanoma to assess serum CEACAM1.
• Monitored serum CEACAM1 levels over time in melanoma patients undergoing immunotherapy.
• Correlated serum CEACAM1 levels with tumor burden and treatment response (progressive disease, stable disease, responders).

Main Results:

• Demonstrated a correlation between serum CEACAM1 levels and tumor burden in the mice xenograft model.
• Observed elevated serum CEACAM1 levels in melanoma patients with progressive disease who did not respond to immunotherapy.
• Showed significantly lower serum CEACAM1 levels in immunotherapy responders and patients with stable disease.

Conclusions:

• Serum CEACAM1 serves as a valuable prognostic biomarker in melanoma.
• Elevated sCEACAM1 levels are associated with clinical deterioration and lack of response to immunotherapy.
• sCEACAM1 holds potential for monitoring melanoma progression and treatment efficacy.